The preliminary efficacy and safety results of neoadjuvant phase II study of anlotinib plus tislelizumab combined with chemotherapy in triple-negative breast cancer.
Authors: Jing Luo, Jie Chen, Xuchu Jin, Liangquan Liu, Lin Zhong, Yi Li, Chihua Wu, Jing Fu, Juan Li